The firm is a venture capital firm based in Western Europe, established in 2020, focused on enabling technologies within life sciences and healthcare. The firm invests from an early-stage fund and typically makes initial investments starting around €1M, with the capacity to deploy additional capital through follow-on rounds totaling several million euros per company. The firm invests across Seed to Series B stages and aims to be a meaningful investor, often leading or co-leading rounds while also participating in syndicates. The firm maintains a regional focus on Western Europe and has an active investment pace with multiple portfolio companies and exits to date.
The firm focuses on diagnostics, medical devices, and digital health opportunities. The firm does not invest in therapeutics and avoids invasive devices, particularly higher-risk regulatory classifications. The firm evaluates companies with regulatory progress and early clinical validation, including those at or around initial clinical stages.
From a company and management team perspective, the firm does not impose strict requirements but takes a hands-on approach to investing. The firm typically requires board representation and works closely with portfolio companies to support growth, development, and commercialization.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment